News

Article

Santen receives marketing authorization application approval from NMPA of China for tafluprost/timolol maleate (Tapcom) in patients with open-angle glaucoma

Key Takeaways

  • Tapcom, a preservative-free combination of tafluprost and timolol, is approved in China for glaucoma and ocular hypertension treatment.
  • Tafluprost and timolol maleate have distinct mechanisms: tafluprost increases aqueous humor outflow, while timolol reduces its production.
SHOW MORE

Tapcom is a preservative-free, fixed-combination eye drop of tafluprost 0.0015% and timolol 0.5% for lowering intraocular pressure.

(Image Credit: AdobeStock/millaf)

(Image Credit: AdobeStock/millaf)

Santen Pharmaceutical has received approval of its marketing authorization application from the National Medical Products Administration (NMPA) of China for tafluprost/timolol maleate (Tapcom) for lowering intraocular pressure (IOP) of patients with open-angle glaucoma or ocular hypertension.

Tapcom is a preservative-free, fixed-combination eye drop of tafluprost 0.0015% and timolol 0.5%. According to the company, Tapcom will be the first preservative-free ophthalmic combination formulation in China containing a first-line prostaglandin derivative.

The two active ingredients have different mechanisms of action on aqueous humor dynamics to lower the IOP. Tafluprost is a prostanoid FP receptor agonist and promotes aqueous humor outflow, while timolol maleate is a nonselective β-receptor blocker and reduces aqueous humor production.

Peter Sallstig, chief medical officer of Santen Pharmaceutical, commented on the approval in a press release from the company.

"Glaucoma remains the leading cause of irreversible blindness worldwide, deeply impacting the quality of life of many patients. Therefore, Santen has prioritized glaucoma as a key therapeutic focus, dedicating ourselves to the development of treatments that meets patients’ needs and the delivery of high-quality ophthalmic drugs. The approval of Tapcom in China represents a significant milestone, offering new treatment options for Chinese glaucoma patients and advancing the field of glaucoma care,” said Sallstig.

References:
  1. Santen announces China NMPA approval of Tapcom in patients with open-angle glaucoma or ocular hypertension. Santen. Published April 4, 2025. Accessed April 7, 2025. https://www.santen.com/en/news/2025/2025_1/20250404

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
© 2025 MJH Life Sciences

All rights reserved.